Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

FDA Intensifies Crackdown on GLP-1 Compounding

FDA Intensifies Crackdown on GLP-1 Compounding
ShareXFacebook

(MedPage Today) -- The FDA is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday. Following a review, the...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement